Journal Club: Risankizumab Long-Term Efficacy in Crohn’s Disease: FORTIFY Extension Results

Thank you to AbbVie for the support on this Journal Club Review Video Module.In this journal club review, Kimberly Orleck, PA-C, discusses the long-term efficacy and safety of risankizumab, an IL-23 p19 inhibitor, in moderate to severely active Crohn’s disease, highlighting results from the FORTIFY maintenance trial and its open-label extension. Data show strong Week 52 clinical remission and endoscopic response and remission rates in both biologic-naïve and biologic-experienced patients, many with prior biologic failure, reinforcing the importance of treat-to-target goals and STRIDE-II recommendations. Long-term findings out to 276 weeks demonstrate sustained clinical and endoscopic outcomes with a favorable safety profile and no new safety signals over four years. The review also covers updated 2025 ACG and AGA guideline positioning and real-world U.S. claims data showing lower treatment switch rates and healthcare utilization with risankizumab compared to other advanced therapies, underscoring its role in evolving Crohn’s disease management. For more educational content, visit the GHAPP digital hub and GHAPP ACE app.